CA2757291A1 — Medical composition for treatment or prophylaxis of glaucoma
Assigned to Ube Corp · Expires 2010-10-07 · 16y expired
What this patent protects
Provided is a pharmaceutical composition for treating or preventing glaucoma, comprising a pyridylamino acetic acid compound represented by general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient. In formula (1), R1, R2, and R3 each independentl…
USPTO Abstract
Provided is a pharmaceutical composition for treating or preventing glaucoma, comprising a pyridylamino acetic acid compound represented by general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient. In formula (1), R1, R2, and R3 each independently represent a hydrogen atom or the like; Y represents a group: -Q1-Q2 (wherein Q1 represents an arylene group or the like; and Q2 represents a group such as an aromatic ring group which may be substituted by a halogen atom or the like) or a dicyclic heteroaromatic ring which may be substituted by a halogen atom or the like; and Z represents a group such as an aromatic ring group which may be substituted by a halogen atom or the like.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.